Yeol-Hong Kim
Fortuna: 377 847 $ al 30/06/2026
Fortuna: 377 847 $ al 30/06/2026
Yeol-Hong Kim is Co-President, Executive Director, and Head of R&D at Yuhan Corp.
since 2024.
Dr. Kim is Non-Executive Director at ProGen Co., Ltd. since 2024.
Dr. Kim is Non-Executive Director at Immuneoncia Therapeutics, Inc. since 2023.
Dr. Kim was Non-Executive Director at Aprilbio Co. Ltd. in 2024.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
YUHAN CORPORATION 0,01 % | 09/06/2026 | 8.339 ( 0,01 % ) | 377 847 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| YUHAN CORPORATION | Presidente | 15/03/2024 |
| PROGEN CO., LTD. | Director/Miembro de la Junta | 28/03/2024 |
| IMMUNEONCIA THERAPEUTICS, INC. | Director/Miembro de la Junta | 26/12/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| APRILBIO CO.,LTD. | Director/Miembro de la Junta | 31/10/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Yuhan Corp.
Yuhan Corp. Pharmaceuticals: MajorHealth Technology Engages in the manufacture and marketing of pharmaceutical products | Health Technology |
Aprilbio Co. Ltd.
Aprilbio Co. Ltd. BiotechnologyHealth Technology Operates as a drug development bio company | Health Technology |
Immuneoncia Therapeutics, Inc.
Immuneoncia Therapeutics, Inc. BiotechnologyHealth Technology Provides drug development and antibody engineering services for oncology patients | Health Technology |
Progen Co., Ltd.
Progen Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of medical sciences and pharmacy products | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.